Early development of anti-natalizumab antibodies in MS patients

Journal of Neurology

Volumn 260, Issue 9, 2013, Pages 2343-2347

  Oliver Martos, B ^a   Orpez Zafra T ^a   Urbaneja, P ^a   Maldonado Sanchez, R ^a   Leyva, L ^a   Fernandez O ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Antibodies; Multiple sclerosis; Natalizumab treatment

Indexed keywords

ANTIBODY; BETA INTERFERON; GLATIRAMER; NATALIZUMAB;

ADULT; ARTICLE; DISEASE DURATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INFUSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; URINARY TRACT INFECTION;

ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; EARLY INTERVENTION (EDUCATION); ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 84884352753     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-6991-2     Document Type: Article

References (9)

1. Stuve O, Bennett JL (2007) Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev 13:79-95. doi: 10.1111/j.1527-3458.2007.00003
2. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910. doi: 10.1056/NEJMoa044397
3. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911-923. doi: 10.1056/NEJMoa044396
4. Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M et al (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69:1391-1403. doi: 10.1212/01.wnl.0000277457.17420.b5
5. Oliver B, Fernández O, Orpez T, Alvarenga MP, Pinto-Medel MJ, Guerrero M et al (2011) Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months. Mult Scler 17(3):368-371. doi: 10.1177/1352458510385508
6. Sørensen PS, Jensen PE, Haghikia A, Lundkvist M, Vedeler C, Sellebjerg F et al (2011) Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler 17(9):1074-1078. doi: 10.1177/1352458511404271
7. Fernández O, Alvarenga MP, Guerrero M, León A, Alonso A, López-Madrona JC et al (2011) The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. Mult Scler 17(2):192-197. doi: 10.1177/1352458510385507
8. Lundkvist M, Hillert J, Fogdell-Hahn A (2010) No increased risk for antibody formation against natalizumab in multiple sclerosis patients positive for neutralizing antibodies to interferon-beta. Mult Scler 16(Suppl. 10):S296. doi: 10.1177/1352458510385507
9. Sorensen PS, Koch-Henriksen N, Jensen X (2011) Neutralizing antibodies against interferon-beta do not predispose antibodies against natalizumab. Neurology 76:759-760. doi: 10.1212/WNL.0b013e31820d62a4